During the past decade, Bracco Diagnostics, Inc. conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Bracco Diagnostics, Inc." are "Liver Neoplasms" (2 trials), "Radiation Exposure" (2 trials), "Renal Insufficiency" (2 trials), "Brain Pathology" (1 trials) and "Brain Tumor" (1 trials). Many other conditions were trialed in "Bracco Diagnostics, Inc." in a lesser frequency.

Most popular intervention types in "Bracco Diagnostics, Inc." are "Drug" (14 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "CardioGen-82" (2 trials), "Iopamidol 370 mgI/mL" (2 trials), "Multihance" (2 trials), "iodixanol" (2 trials) and "Arm 2 - Magnevist" (1 trials). Other intervention names were less common.

The vast majority of trials in "Bracco Diagnostics, Inc." are 16 trials for "All" genders.

Currently, there are NaN active trials in "Bracco Diagnostics, Inc.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Bracco Diagnostics, Inc., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Bracco Diagnostics, Inc., 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 0 trials that are defined as “Not Applicable".